-
Something wrong with this record ?
The impact of tunnel mutations on enzymatic catalysis depends on the tunnel-substrate complementarity and the rate-limiting step
P. Kokkonen, M. Slanska, V. Dockalova, GP. Pinto, EM. Sánchez-Carnerero, J. Damborsky, P. Klán, Z. Prokop, D. Bednar,
Language English Country Netherlands
Document type Journal Article
NLK
Directory of Open Access Journals
from 2012
Free Medical Journals
from 2012
PubMed Central
from 2012
Europe PubMed Central
from 2012 to 2020
Open Access Digital Library
from 2012-01-01
Open Access Digital Library
from 2012-04-01
Open Access Digital Library
from 2012-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2011
- Publication type
- Journal Article MeSH
Transport of ligands between bulk solvent and the buried active sites is a critical event in the catalytic cycle of many enzymes. The rational design of transport pathways is far from trivial due to the lack of knowledge about the effect of mutations on ligand transport. The main and an auxiliary tunnel of haloalkane dehalogenase LinB have been previously engineered for improved dehalogenation of 1,2-dibromoethane (DBE). The first chemical step of DBE conversion was enhanced by L177W mutation in the main tunnel, but the rate-limiting product release was slowed down because the mutation blocked the main access tunnel and hindered protein dynamics. Three additional mutations W140A + F143L + I211L opened-up the auxiliary tunnel and enhanced the product release, making this four-point variant the most efficient catalyst with DBE. Here we study the impact of these mutations on the catalysis of bulky aromatic substrates, 4-(bromomethyl)-6,7-dimethoxycoumarin (COU) and 8-chloromethyl-4,4'-difluoro-3,5-dimethyl-4-bora-3a,4a-diaza-s-indacene (BDP). The rate-limiting step of DBE conversion is the product release, whereas the catalysis of COU and BDP is limited by the chemical step. The catalysis of COU is mainly impaired by the mutation L177W, whereas the conversion of BDP is affected primarily by the mutations W140A + F143L + I211L. The combined computational and kinetic analyses explain the differences in activities between the enzyme-substrate pairs. The effect of tunnel mutations on catalysis depends on the rate-limiting step, the complementarity of the tunnels with the substrates and is clearly specific for each enzyme-substrate pair.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20019423
- 003
- CZ-PrNML
- 005
- 20201123123332.0
- 007
- ta
- 008
- 201103s2020 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.csbj.2020.03.017 $2 doi
- 035 __
- $a (PubMed)32308927
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Kokkonen, Piia $u Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 245 14
- $a The impact of tunnel mutations on enzymatic catalysis depends on the tunnel-substrate complementarity and the rate-limiting step / $c P. Kokkonen, M. Slanska, V. Dockalova, GP. Pinto, EM. Sánchez-Carnerero, J. Damborsky, P. Klán, Z. Prokop, D. Bednar,
- 520 9_
- $a Transport of ligands between bulk solvent and the buried active sites is a critical event in the catalytic cycle of many enzymes. The rational design of transport pathways is far from trivial due to the lack of knowledge about the effect of mutations on ligand transport. The main and an auxiliary tunnel of haloalkane dehalogenase LinB have been previously engineered for improved dehalogenation of 1,2-dibromoethane (DBE). The first chemical step of DBE conversion was enhanced by L177W mutation in the main tunnel, but the rate-limiting product release was slowed down because the mutation blocked the main access tunnel and hindered protein dynamics. Three additional mutations W140A + F143L + I211L opened-up the auxiliary tunnel and enhanced the product release, making this four-point variant the most efficient catalyst with DBE. Here we study the impact of these mutations on the catalysis of bulky aromatic substrates, 4-(bromomethyl)-6,7-dimethoxycoumarin (COU) and 8-chloromethyl-4,4'-difluoro-3,5-dimethyl-4-bora-3a,4a-diaza-s-indacene (BDP). The rate-limiting step of DBE conversion is the product release, whereas the catalysis of COU and BDP is limited by the chemical step. The catalysis of COU is mainly impaired by the mutation L177W, whereas the conversion of BDP is affected primarily by the mutations W140A + F143L + I211L. The combined computational and kinetic analyses explain the differences in activities between the enzyme-substrate pairs. The effect of tunnel mutations on catalysis depends on the rate-limiting step, the complementarity of the tunnels with the substrates and is clearly specific for each enzyme-substrate pair.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Slanska, Michaela $u Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Dockalova, Veronika $u Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Pinto, Gaspar P $u Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic. International Clinical Research Centre, St. Ann's Hospital, Brno, Czech Republic.
- 700 1_
- $a Sánchez-Carnerero, Esther M $u Department of Chemistry and RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Damborsky, Jiri $u Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic. International Clinical Research Centre, St. Ann's Hospital, Brno, Czech Republic.
- 700 1_
- $a Klán, Petr $u Department of Chemistry and RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Prokop, Zbynek $u Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic. International Clinical Research Centre, St. Ann's Hospital, Brno, Czech Republic.
- 700 1_
- $a Bednar, David $u Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic. International Clinical Research Centre, St. Ann's Hospital, Brno, Czech Republic.
- 773 0_
- $w MED00184782 $t Computational and structural biotechnology journal $x 2001-0370 $g Roč. 18, č. - (2020), s. 805-813
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32308927 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201103 $b ABA008
- 991 __
- $a 20201123123331 $b ABA008
- 999 __
- $a ind $b bmc $g 1586200 $s 1109621
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 18 $c - $d 805-813 $e 20200325 $i 2001-0370 $m Computational and structural biotechnology journal $n Comput Struct Biotechnol J $x MED00184782
- LZP __
- $a Pubmed-20201103